Healthcare payments are rapidly emerging as a new battleground in the fight against financial crime. Traditionally viewed as systems vulnerable to billing fraud or abuse, claims processors, telehealth billing platforms and pharmaceutical payment networks are now being exploited for a more complex purpose: laundering illicit funds.
In 2025, US authorities delivered a stark warning. The Department of Justice’s largest ever healthcare fraud takedown charged 324 individuals linked to $14.6bn in false claims, more than double the previous record, said Flagright.
Crucially, investigators found that many of these schemes did not simply siphon money from insurers and public programmes. They layered and laundered proceeds through shell companies, crypto assets and international transfers. Healthcare payment infrastructure is no longer just a fraud vector; it has become an anti-money laundering (AML) concern in its own right.
Regulators have taken note. Financial authorities including FinCEN, alongside health agencies such as HHS, are increasingly urging greater scrutiny of health-related payment flows. Their message is clear: criminals are piggybacking on legitimate healthcare transactions to disguise dirty money. Billing platforms and pharma payment operators that fail to strengthen AML controls risk becoming the weakest link in the financial chain.
Enforcement actions throughout 2025 reinforced this wake-up call. The DOJ highlighted cases where international networks stole patient identities to generate billions in fraudulent claims, then laundered hundreds of millions via crypto wallets and offshore structures. In some instances, insiders allegedly helped move funds abroad while bypassing AML safeguards. Separate conspiracies channelled Medicare payments into private accounts before transferring the money overseas, prompting standalone money laundering charges. Healthcare fraud and money laundering are now deeply intertwined.
FinCEN has also reported a rise in suspicious activity reports tied to healthcare fraud proceeds feeding into broader laundering networks, including those linked to foreign criminal organisations.
At the same time, agencies such as the Centers for Medicare & Medicaid Services are leaning heavily on advanced data analytics to detect anomalous billing and payment behaviour. For platforms operating in healthcare finance, AML risk must now be treated with the same seriousness as fraud risk.
International pharmaceutical trade adds further complexity. Cross-border supply chains can be exploited for trade-based money laundering, including mispriced invoices and shell distributors. Watchdogs have flagged unusual pivots into high-value pharma exports and opaque third-party payment chains as red flags.
Sanctions exposure is another growing risk, particularly where intermediaries obscure ultimate beneficiaries. Payment networks that fail to screen counterparties effectively may inadvertently facilitate sanctioned activity or organised crime.
Despite strict privacy frameworks such as HIPAA, healthcare organisations are permitted to use patient data for fraud detection and compliance activities, provided safeguards are in place.
The Privacy Rule recognises fraud prevention as part of “health care operations”, allowing covered entities and business associates to analyse relevant data without individual authorisation. However, minimum necessary standards, strong access controls and detailed audit logging remain essential.
Strengthening AML defences therefore requires a combination of behavioural analytics, sanctions screening and targeted transaction monitoring. Machine learning models can establish baseline billing patterns and flag sudden deviations.
Rule-based controls can detect unusual refund activity or rapid layering of claim payments. Continuous screening against sanctions lists and high-risk entities is vital, particularly in cross-border pharmaceutical flows. Equally important is secure case management, ensuring investigators can review sensitive data within a fully auditable, privacy-compliant environment.
Far from being a regulatory burden alone, robust AML controls can become a strategic advantage. Strong compliance frameworks reassure banking partners, reduce financial losses and demonstrate resilience under regulatory scrutiny. In a sector built on trust, financial integrity enhances brand value and long-term sustainability.
Healthcare payments can no longer assume AML is someone else’s responsibility. From telehealth startups to large claims processors, embedding advanced AML capabilities is now a product necessity. As enforcement intensifies and criminal tactics evolve, platforms that act decisively will not only protect themselves from regulatory risk but strengthen the foundations of trust on which the entire healthcare ecosystem depends.
Copyright © 2026 RegTech Analyst
Copyright © 2018 RegTech Analyst
